Modality
Gene Therapy
MOA
BTKi
Target
SOS1
Pathway
Sphingolipid
MCL
Development Pipeline
Preclinical
~Oct 2023
→ ~Jan 2025
Phase 1
Apr 2025
→ Mar 2027
Phase 1Current
NCT08667743
2,768 pts·MCL
2025-04→2027-03·Not yet recruiting
2,768 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-2512mo awayPh2 Data· MCL
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2
P1/2
Not yet…
Catalysts
Ph2 Data
2027-03-25 · 12mo away
MCL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08667743 | Phase 1/2 | MCL | Not yet recr... | 2768 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 |